Literature DB >> 11404545

Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus.

S Becker, A Fisher, C Flexner, J G Gerber, R Haubrich, A D Kashuba, A D Luber, S C Piscitelli.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11404545     DOI： 10.1097/00126334-200106010-00018

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  7 in total

Review 1.  Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.

Authors:  Anne-Marie Taburet; Sabine Paci-Bonaventure; Gilles Peytavin; Jean-Michel Molina
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Authors:  Clotilde Le Tiec; Aurélie Barrail; Cécile Goujard; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

Authors:  Dominique Larrey; Ansgar W Lohse; Christian Trepo; Jean-Pierre Bronowicki; Keikawus Arastéh; Marc Bourlière; Jose Luis Calleja; Jerry O Stern; Gerhard Nehmiz; Nasri Abdallah; Kristi L Berger; Martin Marquis; Jürgen Steffgen; George Kukolj
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

Review 4.  Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Authors:  Rob E Aarnoutse; Jonathan M Schapiro; Charles A B Boucher; Yechiel A Hekster; David M Burger
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

Authors:  Dean Hickman; Sudthida Vasavanonda; George Nequist; Lynn Colletti; Warren M Kati; Richard Bertz; Ann Hsu; Dale J Kempf
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

6.  The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.

Authors:  Jianmin Duan; Gordon Bolger; Michel Garneau; Ma'an Amad; Joëlle Batonga; Hélène Montpetit; François Otis; Martin Jutras; Nicole Lapeyre; Manon Rhéaume; George Kukolj; Peter W White; Richard C Bethell; Michael G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

7.  Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.

Authors:  Anne-Marie Taburet; Christophe Piketty; Corine Chazallon; Isabelle Vincent; Laurence Gérard; Vincent Calvez; Francois Clavel; Jean-Pierre Aboulker; Pierre-Marie Girard
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.